Sigma Planning Corp’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sigma Planning Corp’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,383	Closed	-$12.7K	–	1208
2023 Q3	$12.7K	Sell	1,383 -2,000	-59%	-$40.2K	﹤0.01%	1183
2023 Q2	$71.5K	Sell	3,383 -3,429	-50%	-$106K	﹤0.01%	1160
2023 Q1	$183K	Buy	6,812 +2,935	+76%	+$137K	0.01%	1185
2022 Q4	$137K	Buy	3,877 +1,745	+82%	+$210K	﹤0.01%	1172
2022 Q3	$482K	Buy	2,132 +9	+0.4%	+$2.21K	0.02%	744
2022 Q2	$401K	Buy	2,123 +46	+2%	+$9.27K	0.01%	852
2022 Q1	$517K	Sell	2,077 -10	-0.5%	-$1.58K	0.02%	833
2021 Q4	$325K	Buy	2,087 +49	+2%	+$9.48K	0.01%	1045
2021 Q3	$408K	Buy	2,038 +1,506	+283%	+$358K	0.01%	905
2021 Q2	$136K	Buy	532 +25	+5%	+$6.24K	﹤0.01%	1340
2021 Q1	$135K	Hold	507	–	–	﹤0.01%	1266
2020 Q4	$187K	Buy	+507	New	+$145K	0.01%	1121

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sigma Planning Corp's EIGR Position: Q4 2023 in Review

Sigma Planning Corp sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 1,383 shares — an estimated $12.7K sold.

Sigma Planning Corp first reported a position in EIGR in Q4 2020 and held it in 12 quarters. The position peaked at $517K in Q1 2022. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

Sigma Planning Corp reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Sigma Planning Corp sold 1,383 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $12.7K.
Sigma Planning Corp first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2020 and held it in 12 quarters.
Sigma Planning Corp's Eiger BioPharmaceuticals, Inc. position peaked at $517K in Q1 2022.
43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Sigma Planning Corp's 13F filing for Q4 2023, filed 1 Feb 2024.